

FY 2024-25

Annual Impact at a Glance

Unprecedented Times Call for Unprecedented Action



“In moments of disruption, leadership matters. The pace of discovery is accelerating, but the systems that sustain it are strained. Patients with cancer cannot wait for stability to return — they need solutions now. Today, our role as convener and catalyst has never been more essential.”

– Alicia Zhou, PhD, CEO

People × Biology × Data = A World Immune to Cancer

FY 2024-25 By The Numbers



\$33M

New Funding
in 2025



68

New Grants &
Fellowships



41 Institutions

15 U.S. States

5 Countries

In 2025, CRI invested more than **\$33 million in new funding**, supporting **68 new grants and fellowships** across 41 institutions, spanning 15 states in the U.S. and 5 countries worldwide. Each number represents not just dollars or data points, but **lives touched and futures reshaped**.

Since 1953, CRI's investments have driven nearly \$1.2 billion in U.S. economic activity, supported the work of more than 9,500 scientists and researchers, and contributed to lifesaving therapies that now deliver more than **\$30 billion in benefits each year** to patients and families worldwide.

This commitment is best revealed in our central strategy:
People × Biology × Data — the foundation of everything we do to bring the
promise of cancer immunotherapy to patients everywhere.



From investment to impact:

Explore all of the CRI's FY 2024-25 Impact

cancerresearch.org

Responding to a National Need by Empowering Tomorrow's Innovators

In response to financial disruptions at the National Institutes of Health (NIH) in early 2025, CRI pledged an emergency **\$2.5 million to fund an additional 10 fellowships** in response to mounting uncertainty in federal research funding.

Additionally, **CRI extended six months of support to all current fellows** in their final year, ensuring continuity and stability during a turbulent time. Together, these new and continuing fellows represent a bold investment in the future of cancer immunology — and a clear signal of CRI's urgent commitment to **keep progress moving forward**.



If we don't protect this next generation of researchers, we risk losing the very people who will drive the discoveries of tomorrow."


E. John Wherry, PhD

Associate Director, CRI Scientific Advisory Council,
University of Pennsylvania School of Medicine

The 2025 STARS

The CRI Lloyd J. Old STAR Program — **Scientists TAKing Risks** — provides long-term, flexible funding to mid-career scientists, giving them the freedom to pursue high-risk, high-reward research at the **leading edge of cancer immunotherapy**.

One 2025 Awardee, Judith Agudo, PhD, is using the funds to pursue creative, high-risk experiments to investigate how cancer cells escape or resist immune attack, developing sophisticated experimental models that mimic real patient biology.




Patient Resources with Purpose

At CRI, patients aren't just central to our mission — **they're the reason it matters**. Our research has already extended survival worldwide, contributing tens of millions of healthy "life-years" and touching an **estimated 250 million lives** since the first immunotherapy approvals.

To help patients and caregivers navigate treatment, we created **A Patient's Guide to Cancer Immunotherapy** — a plain-language resource co-developed with patients and updated annually to reflect the latest advances.

At our recent **Patient Roundtable**, three stage 4 survivors — among the first in immunotherapy trials — shared how CRI-backed research made their recoveries possible.



Scan to Donate Now



For over 70 years, CRI has turned insights into impact.
Together, we're not just building treatments — we're building a world immune to cancer.